RSV vaccine may shield babies born to mothers with HIV
NCT ID NCT07693166
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study looks at whether the RSV vaccine given in late pregnancy can help protect babies born to mothers with HIV. RSV is a leading cause of infant hospitalization, and babies exposed to HIV are at higher risk. Researchers will measure antibody levels in mothers and infants to see how well protection is passed across the placenta. The study involves 20 pregnant women with HIV and aims to guide future vaccination policies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RSVpreF vaccine (Abrysvo®)
- What this could lead to
- If successful, this could show that the RSV vaccine works in pregnant women with HIV, helping protect their babies from severe RSV illness.
- What could go wrong
- This is a small, early-phase study with only 20 participants, so results may not apply broadly. The vaccine may not transfer enough antibodies to infants in this group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia
- Could intense workouts reverse cognitive decline in older HIV patients?